Tetramethylthiuram monosulfide (Synonyms: TMTM)

Cat. No.: HY-W020246 Purity: 99.71%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Tetramethylthiuram monosulfide (TMTM) is an orally active microsomal monooxygenases inhibitor. Tetramethylthiuram monosulfide is used as an accelerator and activator in the processing of natural rubber and butyl rubber. Tetramethylthiuram monosulfide reduces palmitic acid incorporation into microsomal phospholipids, disrupts microsomal membrane integrity, and impairs electron transport during oxygenation. Tetramethylthiuram monosulfide can be used for the research of fungal infection, bacterial infection and allergic contact dermatitis.

For research use only. We do not sell to patients.

Tetramethylthiuram monosulfide Chemical Structure

CAS No. : 97-74-5

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
25 g	In-stock	Estimated Time of Arrival: December 31
50 g	In-stock	Estimated Time of Arrival: December 31
100 g	In-stock	Estimated Time of Arrival: December 31
250 g	In-stock	Estimated Time of Arrival: December 31
500 g	In-stock	Estimated Time of Arrival: December 31
> 100 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Tetramethylthiuram monosulfide:

Tetramethylthiuram Monosulfide-d₁₂ Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC₅₀	> 5000 μM Compound: 9	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 29216562]

In Vitro

Tetramethylthiuram monosulfide (10-2000 μg/plate; 48 h) induces point mutations in Salmonella typhimurium LT2 strains TA 100 and TA 1535 (especially with metabolic activation) and has a weak mutagenic effect in strain TA 1537, but does not induce mutations in strains TA 98 and TA 1538; higher doses exhibit bacteriotoxicity^[1].
Tetramethylthiuram monosulfide (0.2 ppm; 96 h) is cytotoxic to normal Hartley guinea pig lymph node cells at concentrations of 0.2 ppm and above when incubated with PHA stimulation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tetramethylthiuram monosulfide (26-867 mg/kg; p.o.; single dose or 5 consecutive days per week for 4 weeks) inhibits rat hepatic microsomal monooxygenases at oral doses as low as 26 mg/kg, induces hematological, weight, and histopathological changes with 4-week 26 mg/kg/day dosing, and shows enhanced effects at 867 mg/kg^[1].
Tetramethylthiuram monosulfide (500-2500 mg/kg; p.o.; single dose) has an acute oral LD₅₀ of 818 mg/kg in adult female NMRI mice, with dose-dependent mortality and characteristic intoxication symptoms^[1].
Tetramethylthiuram monosulfide (5%; intradermal injection; epicutaneous via occlusive patch for sensitization; 2.0%; epicutaneous via Finn chamber, 24 hours for challenge) induces contact hypersensitivity in female Hartley guinea pigs, with 62.5% of sensitized animals displaying positive patch test reactions after epicutaneous challenge^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar (adult female, SPF, 180-200 g)^[1]
Dosage:	26 mg/kg; 867 mg/kg
Administration:	p.o.; single dose or 5 consecutive days per week for 4 weeks
Result:	Prolonged hexobarbital sleeping time significantly, and decreased incorporation of [1-¹⁴C] palmitic acid into microsomal phospholipids of isolated perfused livers (26 mg/kg single dose). Left zoxazolamine paralysis time unchanged (26 mg/kg single dose). Prolonged both hexobarbital sleeping time and zoxazolamine paralysis time significantly, and produced a greater decrease in [1-¹⁴C] palmitic acid incorporation into all microsomal phospholipids compared to the 26 mg/kg dose (867 mg/kg single dose). Decreased erythrocyte count from 5.96×10⁶ to 4.32×10⁶ significantly (26 mg/kg/day, 4-week treatment). Decreased hemoglobin content from 14.19 g% to 13.20 g% significantly (26 mg/kg/day, 4-week treatment). Caused initial body weight loss with moderate ongoing reduction, decreased food intake, increased water consumption, increased relative liver weight, and mild histopathological changes including generalized hepatocellular swelling and renal tubular epithelial swelling (26 mg/kg/day, 4-week treatment). Left blood clinicochemical parameters (total protein, BUN, creatinine, alkaline phosphatase, GPT) and hepatic microsomal parameters (protein, cytochrome P-450, glucose-6-phosphatase, malondialdehyde, O-demethylase activity) unchanged (26 mg/kg/day, 4-week treatment).

Animal Model:	NMRI (adult female, 20-25 g, acute toxicity)^[1]
Dosage:	500 mg/kg; 750 mg/kg; 1000 mg/kg; 1250 mg/kg; 1500 mg/kg; 2000 mg/kg; 2250 mg/kg; 2500 mg/kg
Administration:	p.o.; single dose
Result:	Resulted in an acute oral LD₅₀ of 818 mg/kg. Caused intoxication symptoms including tachypnea, tachycardia, miosis, rare convulsions, and extremity paralysis. Showed dose-dependent mortality onset, varying from 1 hour (2500 mg/kg) to 24 hours across doses.

Animal Model:	Hartley (female, 300-400 g)^[3]
Dosage:	5% (sensitization); 2.0% (challenge)
Administration:	intradermal injection; epicutaneous via occlusive patch (sensitization); epicutaneous via Finn chamber, 24 hours (challenge)
Result:	Induced positive patch test reactions in 62.5% of sensitized guinea pigs. Induced doubtful reactions in 25% of sensitized guinea pigs. Induced negative reactions in 12.5% of sensitized guinea pigs. Resulted in negative reactions in all control guinea pigs.

Molecular Weight

208.37

Formula

C₆H₁₂N₂S₃

CAS No.

97-74-5

Appearance

Solid

Color

Light yellow to yellow

SMILES

S=C(SC(N(C)C)=S)N(C)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 200 mg/mL (959.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.7992 mL	23.9958 mL	47.9916 mL
5 mM	0.9598 mL	4.7992 mL	9.5983 mL
10 mM	0.4799 mL	2.3996 mL	4.7992 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (9.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (9.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.71%

Select Batch:

Data Sheet (276 KB) SDS (597 KB)

COA (245 KB) HNMR (124 KB) LCMS (96 KB)

Handling Instructions (2659 KB)

References

[1]. Alanis OT, et al. Toxicity studies on tetramethylthiuram monosulfide. Environ Res. 1982 Jun;28(1):199-211.

[2]. Li Q, et al. Evaluation of contact sensitivity to formaldehyde and tetramethylthiuram monosulfide using a modified lymphocyte transformation test. Toxicology. 1995;104(1-3):17-23.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.7992 mL	23.9958 mL	47.9916 mL	119.9789 mL
	5 mM	0.9598 mL	4.7992 mL	9.5983 mL	23.9958 mL
	10 mM	0.4799 mL	2.3996 mL	4.7992 mL	11.9979 mL
	15 mM	0.3199 mL	1.5997 mL	3.1994 mL	7.9986 mL
	20 mM	0.2400 mL	1.1998 mL	2.3996 mL	5.9989 mL
	25 mM	0.1920 mL	0.9598 mL	1.9197 mL	4.7992 mL
	30 mM	0.1600 mL	0.7999 mL	1.5997 mL	3.9993 mL
	40 mM	0.1200 mL	0.5999 mL	1.1998 mL	2.9995 mL
	50 mM	0.0960 mL	0.4799 mL	0.9598 mL	2.3996 mL
	60 mM	0.0800 mL	0.3999 mL	0.7999 mL	1.9996 mL
	80 mM	0.0600 mL	0.2999 mL	0.5999 mL	1.4997 mL
	100 mM	0.0480 mL	0.2400 mL	0.4799 mL	1.1998 mL

Tetramethylthiuram monosulfide Related Classifications

Inflammation/Immunology Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tetramethylthiuram monosulfide97-74-5TMTMSqualene MonooxygenaseBacterialSqualene Monooxygenase, SQLE, Squalene Epoxidasemicrosomal aliphatic hydroxylasesuccinic dehydrogenasecytochrome oxidaseSalmonella typhimurium LT2 strains TA 100microsomal phospholipidsfemale NMRI micepalmitic acidallergic contact dermatitisHartley guinea pig lymph node cellsSalmonella typhimurium LT2 strains TA 1535Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *